Swiss National Bank’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Swiss National Bank’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-59,400	Closed	-$2.85M	–	2587
2020 Q1	$2.85M	Buy	59,400 +900	+2%	+$41.9K	﹤0.01%	1233
2019 Q4	$2.75M	Buy	58,500 +7,000	+14%	+$309K	﹤0.01%	1542
2019 Q3	$1.22M	Buy	51,500 +2,200	+4%	+$65.2K	﹤0.01%	1956
2019 Q2	$1.48M	Buy	49,300 +1,700	+4%	+$38.9K	﹤0.01%	1887
2019 Q1	$1.07M	Hold	47,600	–	–	﹤0.01%	2027
2018 Q4	$866K	Buy	+47,600	New	+$747K	﹤0.01%	2084
2018 Q2	–	Sell	-33,400	Closed	-$177K	–	2546
2018 Q1	$177K	Buy	33,400 +20,200	+153%	+$144K	﹤0.01%	2477
2017 Q4	$112K	Hold	13,200	–	–	﹤0.01%	2512
2017 Q3	$193K	Hold	13,200	–	–	﹤0.01%	2517
2017 Q2	$247K	Buy	+13,200	New	+$298K	﹤0.01%	2542

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Swiss National Bank's RARX Position: Q2 2020 in Review

Swiss National Bank sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 59,400 shares — an estimated $2.85M sold.

Swiss National Bank first reported a position in RARX in Q2 2017 and held it in 10 quarters. The position peaked at $2.85M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Swiss National Bank reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Swiss National Bank sold 59,400 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.85M.
Swiss National Bank first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 10 quarters.
Swiss National Bank's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.85M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.